Athenex Announces Second Quarter 2017 Results
BUFFALO, N.Y., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced its financial results and business highlights for the second quarter of 2017.
“We are excited to report a transformational second quarter for our Company as we work to establish Athenex as a leader in the global biopharmaceutical oncology space. We successfully completed our initial public offering on Nasdaq, strengthening our balance sheet and providing further funding to advance our drug candidates through clinical trials, as well as ramp up our global operations,” stated Johnson Lau, Athenex’s Chairman and Chief Executive Officer. “During the quarter, we announced the submission of an IND application of Oraxol, our lead candidate in the Orascovery platform, to the Chinese FDA, and commenced our Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in gastric cancer. We also received IND approval from the Chinese FDA for the KX-02 tablet in our Src Kinase platform. We are pleased with the progress made across our proprietary platforms and expect to build upon this momentum as we work to advance our broad pipeline.”
“We are excited to report a transformational second quarter for our Company as we work to establish Athenex as a leader in the global biopharmaceutical oncology space. We successfully completed our initial public offering on Nasdaq, strengthening our balance sheet and providing further funding to advance our drug candidates through clinical trials, as well as ramp up our global operations,” stated Johnson Lau, Athenex’s Chairman and Chief Executive Officer. “During the quarter, we announced the submission of an IND application of Oraxol, our lead candidate in the Orascovery platform, to the Chinese FDA, and commenced our Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in gastric cancer. We also received IND approval from the Chinese FDA for the KX-02 tablet in our Src Kinase platform. We are pleased with the progress made across our proprietary platforms and expect to build upon this momentum as we work to advance our broad pipeline.”